Brief: Transgene Q3 Operating Income Down At 1.8 Million Euros

Transgene SA

04/11/2021 17:33

Nov 4 (Reuters) - Transgene SA  TRNG.PA :
    * EUR 40.9 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER
30, 2021
    * FINANCIAL VISIBILITY UNTIL END OF 2023
    * EUR 40.9 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER
30, 2021, FURTHER STRENGTHENED BY EUR 17.4 MILLION RECEIVED IN
OCTOBER 2021 FROM PARTIAL SALE OF TASLY BIOPHARMACEUTICALS
SHARES
    * DURING FIRST NINE MONTHS OF 2021 GOVERNMENT FINANCING FOR
RESEARCH EXPENDITURES, MAINLY IN FORM OF A RESEARCH TAX CREDIT,
AMOUNTED TO EUR 4.9 MILLION
    * IN Q4 2021 TRANSGENE AND BIOINVENT WILL PRESENT
PRECLINICAL DATA
ON THEIR NOVEL DUAL MECHANISM-OF-ACTION ONCOLYTIC VACCINIA VIRUS
BT-001
    * Q3 OPERATING INCOME EUR 1.8 MILLION VERSUS EUR 2 MILLION
YEAR
AGO
    * Q3 REVENUE FROM COLLABORATIVE AND LICENSING AGREEMENTS EUR
0.2
MILLION VERSUS EUR 0.4 MILLION YEAR AGO

Source text for Eikon:  ID:nBw1vDVfBa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))